Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
Toni K. Choueiri, Chris Labaki, Ziad Bakouny, et al.
The Lancet Regional Health - Americas (2023) Vol. 19, pp. 100445-100445
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
Andrea Antinori, Mary T. Bausch-Jurken
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S4-S12
Open Access | Times Cited: 44
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1699-1721
Closed Access | Times Cited: 17
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
Victoria Hall, Benjamin W. Teh
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S55-S69
Open Access | Times Cited: 11
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
Rebecca Hasseli, Jutta Richter, Bimba F. Hoyer, et al.
RMD Open (2023) Vol. 9, Iss. 2, pp. e002998-e002998
Open Access | Times Cited: 10
Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile
Jacob New, Jason Cham, Lana Smith, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008233-e008233
Open Access | Times Cited: 3
Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination
Anthony M. Kyriakopoulos, Greg Nigh, Peter A. McCullough, et al.
Authorea (Authorea) (2024)
Open Access | Times Cited: 3
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity
Sunil J. Wimalawansa
Heliyon (2024) Vol. 10, Iss. 15, pp. e34691-e34691
Open Access | Times Cited: 3
A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
Prashant Dogra, Carmine Schiavone, Zhihui Wang, et al.
JCI Insight (2023) Vol. 8, Iss. 13
Open Access | Times Cited: 8
Oral antivirals for COVID-19 among patients with cancer
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 8
Closed Access | Times Cited: 2
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
Panos Arvanitis, Alexis Hope Lerner, Kendra Vieira, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 2739-2748
Open Access | Times Cited: 5
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Current Oncology (2023) Vol. 30, Iss. 5, pp. 5103-5115
Open Access | Times Cited: 5
Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves
Zachary M. Avigan, Rodrigo Paredes, Leora Boussi, et al.
Cancer Medicine (2023) Vol. 12, Iss. 16, pp. 16869-16875
Open Access | Times Cited: 5
Oral antivirals for COVID-19 among patients with cancer
Dorra Guermazi, Panos Arvanitis, Kendra Vieira, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Evangelos Terpos, A.R. Branagan, Ramón García‐Sánz, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 107-112
Open Access | Times Cited: 3
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
Fabrizio Nelli, Diana Giannarelli, Agnese Fabbri, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 10, pp. 3217-3228
Open Access | Times Cited: 3
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
Fabrizio Nelli, Carlo Signorelli, Agnese Fabbri, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3625-3625
Open Access | Times Cited: 3
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study
Fabrizio Nelli, Agnese Fabbri, Andrea Botticelli, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
The Impact of Withholding Cost-Effective Early Treatments, such as Vitamin D, on COVID-19: An Analysis Using an Innovative Logical ParadigmThe Impact of Withholding Cost-Effective Early Treatments, such as Vitamin D, on COVID-19: An Analysis Using an Inno
Athula K. Polonowita, Sunil J. Wimalawansa
World Journal of Advanced Pharmaceutical and Life Sciences (2023) Vol. 5, Iss. 2, pp. 013-034
Open Access | Times Cited: 3
The potential of mRNA vaccine in HCC treatment
Rui Han
International Journal of Immunotherapy and Cancer Research (2023) Vol. 9, Iss. 1, pp. 008-012
Open Access | Times Cited: 2
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study
Cecilia A. Castellano, Tianyi Sun, Deepak Ravindranathan, et al.
Cancer (2024) Vol. 130, Iss. 12, pp. 2191-2204
Closed Access
Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes
Urška Janžič, Andrej Janžič, Abed Agbarya, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 535-535
Open Access
Long-Term Immunological Alertness and Response to COVID-19 Vaccination—Conditions for Prevention in Early Palliative Oncological Care Patients
Peter Priester, Miroslav Fajfr, Veronika Molnárová, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 299-299
Open Access
Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies
Hui-Eon Lee, Na‐Young Jeong, Eun‐Cheol Park, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 5, pp. 854-861
Open Access
Linking COVID-19 and cancer: Underlying mechanism
Sourabh Tyagi, Nipanshi Tyagi, A. K. Singh, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1871, Iss. 1, pp. 167563-167563
Closed Access
Page 1 - Next Page

Scroll to top